{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:37Z","timestamp":1787010037272,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>\n                    Pandrug-resistant (PDR) bacterial infections in intensive care units are emerging as a severe problem. Therefore, new antibiotic options are urgently needed for the treatment of PDR infections in pediatric age groups, especially neonates. Herein, we report a 25 days old preterm neonate successfully treated with ceftazidime-avibactam due to a urinary tract infection caused by PDR\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    . We aimed to describe our experiences about the safety and efficacy of ceftazidime-avibactam treatment.\n                  <\/jats:p>","DOI":"10.1097\/inf.0000000000002807","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T22:05:33Z","timestamp":1593727533000},"page":"854-856","source":"Crossref","is-referenced-by-count":34,"title":["Successful Treatment of Pandrug-resistant Klebsiella pneumoniae Infection With Ceftazidime-avibactam in a Preterm Infant"],"prefix":"10.1097","volume":"39","author":[{"given":"Yesim","family":"Coskun","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Bahcesehir University School of Medicine, Medical Park Goztepe Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Atici","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Disease, Department of Pediatrics, Okan University School of Medicine, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections.","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia.","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0000000000002344","article-title":"Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age.","volume":"38","author":"Iosifidis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14787210.2017.1318064","article-title":"Use of tigecycline in pediatric clinical practice.","volume":"15","author":"Mastrolia","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients.","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/1573396314666180308150908","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: novel therapy for multidrug resistant gram negative infections in children.","volume":"14","author":"Rodriguez","year":"2018","journal-title":"Curr Pediatr Rev"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T19:10:49Z","timestamp":1694545849000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002807"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002807","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}